Injection, mirvetuximab soravtansine-gynx, 1 mg
Drugs administered other than oral method, chemotherapy drugs
J9063 is a valid 2024 HCPCS code for Injection, mirvetuximab soravtansine-gynx, 1 mg or just “Inj, elahere, 1 mg” for short, used in Medical care.
HCPCS Level II Code Drugs administered other than oral method, chemotherapy drugs |
|
HCPCS Code | J9063 |
---|---|
Description |
Long description:
Short description: |
HCPCS Modifier1 | |
HCPCS Pricing indicator |
51 - Drugs
|
Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
Coverage code | C - Carrier judgment |
ASC payment group code | Effective Jul 01, 2023 - This procedure is approved to be performed in an ambulatory surgical center. |
BETOS2 code | O1D - Chemotherapy |
HCPCS Action code | N - No maintenance for this code |
Type of service | 1 - Medical care |
Effective date | Effective Jul 01, 2023 |
Date added | Added Jul 01, 2023 |
HCPCS Coding Procedures |
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
Effective | Code Dosage | Payment Limit |
Vaccine AWP % | Vaccine Limit | Infusion AWP % | DME infusion limit | Blood AWP % | Blood limit | Clotting factor | Note |
---|---|---|---|---|---|---|---|---|---|---|
October 1, 2024 - December 31, 2024 | 1 MG | 66.758 | - | - | - | - | - | - | ||
Jul 1, 2024 - Sep 30, 2024 | 1 MG | 66.865 | - | - | - | - | - | - | ||
April 1, 2024 - June 30, 2024 | 1 MG | 65.682 | - | - | - | - | - | - | ||
January 1, 2024 - March 31, 2024 | 1 MG | 65.71 | - | - | - | - | - | - | ||
October 1, 2023 - December 31, 2023 | 1 MG | 65.754 | 20% | - | - | - | - | - |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”